ArticleCureus2025
Pregabalin as a Potential Adjunct in the Management of Pruritus in Prurigo Nodularis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prurigo nodularis (PN) is a chronic inflammatory skin disorder characterized by intense pruritus and hyperkeratotic nodules. Pregabalin, a γ-aminobutyric acid (GABA) analogue commonly used for neuropathic pain, has shown promise in alleviating chronic pruritus, including PN. Although not currently approved for the treatment of PN or chronic pruritus, pregabalin is considered a promising off-label therapeutic option. We report the case of a 69-year-old woman with PN who achieved complete resolution of skin lesions and marked improvement in pruritus following treatment with nemolizumab. However, after discontinuation of pregabalin, which had been prescribed for coexisting sciatic pain, the patient experienced a recurrence of pruritus over the course of two months, despite the continued absence of visible skin lesions. Reintroduction of low-dose pregabalin led to symptom stabilization within two months, suggesting that pregabalin may have contributed to the control of pruritus. Pregabalin may exert antipruritic effects by inhibiting the α2δ subunit of voltage-gated calcium channels and suppressing the release of excitatory neurotransmitters such as substance P and calcitonin gene-related peptide. This case highlights the potential utility of pregabalin in managing PN-associated pruritus, particularly in cases with a suspected neuropathic itch component. Further clinical studies are warranted to clarify the efficacy of pregabalin and better define its role as an adjunctive treatment for chronic pruritus in PN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.